Atreca Inc (OTCPK:BCEL)
$ 0.09 -0.0012 (-1.32%) Market Cap: 3.57 Mil Enterprise Value: -16.54 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Atreca Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript

Dec 01, 2022 / 02:40PM GMT
Release Date Price: $1.04 (-2.80%)
Josh Schimmer
Evercore ISI - Analyst

This is Josh Schimmer from the Evercore ISI Biotech team. Very pleased to introduce. From Atreca, we have John Orwin, President and Chief Executive Officer; Steven Gould, Chief Scientific Officer; Herb Cross, Chief Financial Officer; Tito Serafini, Chief Strategy Officer; and we also have Alex Gray from Corporate Communications with us.

So gentlemen, welcome. Thanks so much for joining. Why don't we just kind of start with a snapshot of Atreca's platform and where you are in that division kind of company.

John Orwin
Atreca, Inc. - President and CEO

Sure. And I'll take that one unless you want to dive deeper into the platform. But essentially, we have a validated platform that allows us to discover novel antibody target pairs by interrogating the human immune response platform involves high-throughput sequencing of B cell plasmablasts of our serial samples so that we can look at the emergence or expansion or persistence of different B cell clones that help us to identify antibodies that may be important in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot